The KEYNOTE-158 trial investigated pembrolizumab in non-colorectal microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) cancers, including patients with anal cancers, showing an 11% response rate overall and a 15% rate in PD-L1-positive patients. Here, CD274 is linked to cancer.